{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-038108","form_type":"8-K","ticker":"SVRA","cik":"0001160308","company_name":"Savara Inc","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.529521+00:00","generated_at":"2026-06-06T00:03:48.913705+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Savara enters master services agreement with Fujifilm for molgramostim manufacturing","bullets":["Agreement covers development and manufacturing services for molgramostim active pharmaceutical ingredient.","Scope of Work #03 executed for Process Performance Qualification manufacturing campaign.","Either party may terminate with three months' notice if no scope-of-work activities are in process.","Termination also allowed for material uncured breach or unforeseen technical issues by Fujifilm.","Includes standard provisions on confidentiality, intellectual property, liability, and indemnification."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-038108","json":"https://secwatch.observer/filing/0001193125-24-038108.json","markdown":"https://secwatch.observer/filing/0001193125-24-038108.md","text":"https://secwatch.observer/filing/0001193125-24-038108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1160308/000119312524038108/0001193125-24-038108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1160308/000119312524038108/d775782d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:03:48.913705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d28d2203059c1906fff66be5a9ffb376f49a1252","claim":"Savara Inc entered into Master Services Agreement with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”) (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, Savara Inc. (the “Company”) entered into a Master Services Agreement (the “Agreement”) with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”), pursuant to which Fujifilm will continue to provide development and manufacturing services related to active pharmaceutical ingredient for the Company’s molgramostim product candidate in accordance with the terms of separate scope of work agreements to be entered into by the parties.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1160308/000119312524038108/0001193125-24-038108-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. (collectively, “Fujifilm”)"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}